FDA Pediatric Incentives, Powers Would Become Permanent Under Draft Bill
Executive Summary
In the absence of sunset provisions that necessitate periodic reauthorization of the pediatric laws, GAO would report to Congress on a five-year cycle about the accomplishments of the drug programs for children and make recommendations for amendments.